Features
Get A Demo
Plans
Sign Up
Login
All Federal Grant Programs
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Posted
8/21/18
Assistance Listing Number
93.840
Overview
Grant Opportunities
492
Grant Awards
11
Federal Agency
National Institutes of Health
Applicant Types
Not listed
Beneficiary Types
Not listed
Additional Information
Not listed
Popular Federal Grant Opportunities
Not listed
Popular Federal Grant Awards
Not listed
Name
Description
Awardee
Assistance Type
Dollars Obligated
(Click to sort descending)
Award Date
(Click to sort descending)
Updated At
(Click to sort descending)
NU38DP000011
MINNESOTA'S SUDDEN UNEXPECTED INFANT DEATH AND SUDDEN DEATH IN THE YOUNG CASE REGISTRY
Minnesota Department Of Health
Cooperative Agreement
$936.2k
9/30/18
9/20/24
NU58DP007712
SUDDEN UNEXPECTED INFANT DEATH AND SUDDEN DEATH IN THE YOUNG CASE REGISTRY - PROJECT ABSTRACT SUMMARY THE FATALITY REVIEW PROGRAM (FRP) IS A UNIT OF THE PHILADELPHIA MEDICAL EXAMINER'S OFFICE, WHICH IS A DIVISION OF THE PHILADELPHIA DEPARTMENT OF PUBLIC HEALTH. THE FRP MANAGES THE LOCAL CHILD DEATH REVIEW (CDR) TEAM FOR PHILADELPHIA COUNTY AND IS RESPONSIBLE FOR REVIEWING ALL DEATHS OF PHILADELPHIA CHILDREN FROM BIRTH TO 21 YEARS - INCLUDING GATHERING INFORMATION FROM LOCAL AGENCIES, ENTERING ALL DATA INTO THE NATIONAL CENTER FOR FATALITY REVIEW AND PREVENTION CASE REPORTING SYSTEM (NFR-CRS), AND CONTRIBUTING TO HEALTH PROMOTION AND MORTALITY PREVENTION ACTIVITIES. IN 2019, THE FRP WAS AWARDED A GRANT (UNDER THE AUSPICES OF THE PENNSYLVANIA DEPARTMENT OF HEALTH) TO CARRY OUT THE SUID AND SDY CASE REGISTRY PROJECT FOR PHILADELPHIA COUNTY. THE FRP IS APPLYING AGAIN TO BE A RECIPIENT OF THE SUID AND SDY CASE REGISTRY, BUT THIS TIME AS A DIRECT GRANTEE. THE PURPOSE OF THIS PROJECT IS FOR THE FRP TO IMPROVE ITS OVERALL ABILITY TO PERFORM THE CORE FUNCTIONS OF THE SUID AND SDY CASE REGISTRY. SOME OF OUR DESIRED OUTCOMES ARE TO IDENTIFY SUID/SDY CASES IN A CONSISTENTLY TIMELY MANNER, ENTER DATA INTO THE NFR-CRS IN A MORE COMPLETE AND TIMELY MANNER, PERFORM QUALITY CHECKS ON ALL OUR SUID/SDY DATA, AND DISSEMINATE OUR DATA TO INTERNAL AND EXTERNAL PARTNERS. THE ULTIMATE GOAL OF THIS PROJECT IS TO INCREASE THE NUMBER OF DATA-DRIVEN, INFORMED PRACTICE AND POLICY CHANGES, WHICH IN TURN WILL HOPEFULLY DECREASE SUID/SDY RATES AND REDUCE DISPARITIES. THIS APPLICATION BUILDS UPON THE EXPERIENCE AND LESSONS LEARNED FROM PARTICIPATING IN THE LAST 5-YEAR CYCLE OF THE SUID AND SDY CASE REGISTRY. THE FRP HOPES AND ANTICIPATES CONTINUING TO BE A NATIONAL LEADER IN SUID/SDY DATA EXCELLENCE AND QUALITY AS WELL AS OBTAINING CONSENTS FOR THE SDY BIOREPOSITORY. THE FRP ALSO EXPECTS TO GREATLY IMPROVE IN OTHER IMPORTANT OUTCOMES OF THE SUID AND SDY REGISTRY WHERE IT HAS PREVIOUSLY LAGGED COMPARED TO ITS PEERS.
City Of Philadelphia
Cooperative Agreement
$449.4k
9/30/23
12/9/24
NU58DP007700
SAN FRANCISCO SUDDEN UNEXPECTED INFANT DEATH (SUID) AND SUDDEN DEATH IN THE YOUNG (SDY) CASE REGISTRY: SUID COMPONENT A AND SDY COMPONENT B - SUDDEN UNEXPECTED INFANT DEATH (SUID) AND SUDDEN DEATH IN THE YOUNG (SDY) ARE CRITICAL PUBLIC HEALTH ISSUES WITH DEVASTATING IMPACTS ON FAMILIES, CARE PROVIDERS, AND THE COMMUNITY. HISTORICALLY, CAUSES OF DEATH IN YOUNG POPULATIONS HAVE BEEN POORLY STUDIED AND CLASSIFIED, LEADING TO INACCURATE INCIDENCE DATA FROM WHICH PUBLIC HEALTH INTERVENTIONS CAN BE APPLIED. FURTHERMORE, THE GLOBAL COVID-19 PANDEMIC HAS MAGNIFIED HEALTHCARE DISPARITIES, REVEALING A DIRE NEED FOR CONTINUED SURVEILLANCE OF SUID/SDY IN VULNERABLE COMMUNITIES. THE PRINCIPAL INVESTIGATOR (PI) OF THIS APPLICATION, ZIAN TSENG, HAS ESTABLISHED THE NECESSARY INFRASTRUCTURE AND MULTIDISCIPLINARY COLLABORATIONS, INCLUDING CARDIAC ELECTROPHYSIOLOGY, PEDIATRIC CARDIOLOGY, FORENSIC PATHOLOGY, NEUROLOGY, EPILEPTOLOGY, GENETIC COUNSELING, AND CHILD DEATH REVIEW TEAM LEADERS, FOR A SUCCESSFUL EXTENSION OF OUR INVOLVEMENT WITH THE SUID AND SDY CASE REGISTRY. OUR NHLBI-FUNDED, ONGOING SAN FRANCISCO POST SCD (POSTMORTEM SYSTEMATIC INVESTIGATION OF SUDDEN CARDIAC DEATH) STUDY ESTABLISHED A HIGHLY SUCCESSFUL COLLABORATION WITH THE SAN FRANCISCO MEDICAL EXAMINER TO FULLY INVESTIGATE AND AUTOPSY ALL ADULT SUDDEN DEATHS SINCE 2011. AS ONE OF THE ORIGINAL CDC SUID AND SDY CASE REGISTRY GRANTEES IN 2015, WE WERE ABLE TO LEVERAGE THIS COLLABORATION TO ACCURATELY DESCRIBE THE INCIDENCE AND EPIDEMIOLOGY OF SUID/SDY IN SAN FRANCISCO. THIS ALLOWED US TO IDENTIFY DISPARITIES, PROMOTE EQUITABLE INVESTIGATIONS, AND GUIDE SUID/SDY PREVENTION MEASURES. WE PROPOSE THE EXTENSION OF THESE ACTIVITIES AND COLLABORATIONS TO CONTINUE TO FULLY INVESTIGATE ALL INCIDENT SUID/SDY IN SAN FRANCISCO WITH COMPLETE CAPTURE OF DATA, INCLUDING AUTOPSY/PATHOLOGY REPORTS, DEATH CERTIFICATES, MEDICAL RECORDS, PARAMEDIC RUNSHEETS, DEATH SCENE AND POLICE INVESTIGATION, BIOSPECIMEN COLLECTION, GENETIC TESTING. EVERY SUID/SDY CASE WILL BE REVIEWED IN A TIMELY MANNER BY THE CHILD DEATH REVIEW (CDR) TEAM AND CLINICAL ADVANCED REVIEW TEAM AND CATEGORIZED ACCORDING TO THE CDC'S ALGORITHM. ON CASES WHERE WE SUCCESSFULLY ENGAGE FAMILY MEMBERS TO CONSENT FOR ACCESS TO AUTOPSY TISSUE SPECIMENS FOR MOLECULAR AND GENETIC ANALYSES, WE WILL PROVIDE CLINICAL SCREENING RECOMMENDATIONS AND GENETIC COUNSELING TO AT-RISK FAMILIES. OUTCOMES INCLUDE: (1) MAINTAIN COMPLETENESS, TIMELINESS, AND QUALITY OF SUID AND SDY SURVEILLANCE DATA, PARTICULARLY WITH RESPECT TO SOCIAL DETERMINANTS OF HEALTH (SDOH), FOR PROGRAM IMPROVEMENT AND PUBLIC HEALTH PURPOSES. (2) INCREASE THE DISSEMINATION OF DATA BRIEFS AND OTHER PRODUCTS TO INFORM INTERNAL AND EXTERNAL STAKEHOLDERS, INCLUDING BUT NOT LIMITED TO DEATH INVESTIGATORS, SAFE-SLEEP ORGANIZATIONS, AND PUBLIC HEALTH OFFICIALS. (3) INCREASE IN THE NUMBER OF IMPLEMENTED POLICIES AND PRACTICES TO STANDARDIZE AND REDUCE INEQUITY IN INVESTIGATION PRACTICES, INCLUDING REVIEW OF MEDICAL RECORDS, SCENE INVESTIGATION AND AUTOPSY PROTOCOLS. OUR TEAM IS COMMITTED TO SUPPORTING OTHER CDC REGISTRY SITES AND ARE AVAILABLE FOR CONSULTATIONS ON CARDIAC PATHOLOGY AND EVALUATION OF CARDIAC DEVICES. AS A CLINICAL AND RESEARCH INSTITUTION WITH A UNIQUE PERSPECTIVE ON SDY/SUID CASES, WE WILL CONTRIBUTE OUR INSIGHTS TOWARDS THE NATIONWIDE REGISTRY BEYOND THE SCOPE OF OUR LOCAL CASES.
The Regents Of The University Of California. San Francisco
Cooperative Agreement
$301.8k
9/30/23
8/1/24
R61HL143324
ENHANCING CARDIAC AND PULMONARY REHABILITATION ADHERENCE THROUGH HOME-BASED REHABILITATION AND BEHAVIORAL NUDGES: ERA NUDGE
Denver Health And Hospital Authority
Project Grant
$410.4k
9/17/18
3/10/20
NU58DP007704
MICHIGAN SUDDEN UNEXPECTED INFANT DEATH AND SUDDEN DEATH IN THE YOUNG CASE REGISTRY
Michigan Public Health Institute
Cooperative Agreement
$1.0m
9/30/23
8/1/24
Name
Description
Solicitation Number
Federal Agency
Due Date
(Click to sort descending)
Posted Date
(Click to sort descending)
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.
RFA-NS-23-007
Department of Health and Human Services National Institutes of Health
4/4/25
9/15/22
Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets (R01 Clinical Trial Not Allowed)
Basic research in the area of HIV-associated comorbidities has generally focused on the analysis of a pathway or a potential mechanism that contributes to the development of a single, specific HIV-associated comorbidity or end-organ disease. However, evidence indicates that there could be shared biological mechanisms that underlie the development of certain comorbidities, especially in the context of HIV infection. Targeting these mechanisms may not only impact HIV-associated comorbidities, but also have an impact on HIV cure and help elucidate underlying mechanisms of HIV disease pathogenesis. Through the formation of multidisciplinary teams, this initiative aims to uncover the pathophysiologic mechanisms that drive biological aging and age-related comorbidities in people living with HIV. This Funding Opportunity Announcement (FOA) seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple heart, lung, blood, and sleep (HLBS)-related comorbidities associated with HIV infection.
PAR-21-027
Department of Health and Human Services National Institutes of Health
1/7/23
9/30/20
HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotype participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain.
RFA-AT-22-005
Department of Health and Human Services National Institutes of Health
12/15/21
10/29/21
Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P41)
The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active P41 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
RFA-HL-17-033
Department of Health and Human Services National Institutes of Health
6/26/17
4/28/17
PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed
This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.
PA-19-272
Department of Health and Human Services National Institutes of Health
7/6/20
5/7/19